August 2024 Journal Review

Prepared By
Xavier Escoda Llorens, DVM, Resident ECVIM-CA (Oncology)
Large Granular Lymphocyte Lymphoma in 65 Dogs (2005–2023)
Andrew D. Yale, Asia L. Crawford, Irina Gramer, Alexandra Guillén, Isabelle Desmas, Emma J. Holmes
Veterinary and Comparative Oncology, 2024; Vol 22: pp. 115–124 https://onlinelibrary.wiley.com/doi/10.1111/vco.12959
Background
This article investigates large granular lymphocyte lymphoma (LGLL) in dogs, a rare and highly aggressive lymphoma subtype, which originates from either cytotoxic T-cells (T-LGL) or natural killer cells (NK-LGL). Previous studies have mainly been limited to case reports, making this the largest study of canine LGLL, aiming to provide a comprehensive analysis of clinical presentation, disease behavior, prognostic factors, and treatment outcomes.
Study Design
This retrospective study was conducted at the Royal Veterinary College in the UK, reviewing medical records from 2005 to 2023. The study included dogs diagnosed with LGLL, focusing on clinical data, diagnostics, treatments, and outcomes.
Animals
65 dogs
Methods
Data were collected on clinical signs, hematological and biochemical profiles, cytology, histopathology, and imaging results. Treatment responses were evaluated using the Veterinary Cooperative Oncology Group (VCOG) criteria. Statistical analyses included Kaplan-Meier survival curves to estimate median survival times and progression-free intervals. Cox proportional hazards models were applied to assess the impact of various clinical and pathological factors (e.g., lymphocyte size, blood involvement) on survival outcomes. Significance was set at p < 0.05.
Results
The study included 65 dogs, with Labrador Retrievers being the most represented breed (29.2%). The predominant forms of LGLL were hepatosplenic (32.8%) and gastrointestinal (20.7%), with peripheral blood or bone marrow involvement in 30.8% of cases. Twenty-two dogs were euthanized at the time of diagnosis. Of the remaining 43 dogs, 32 were treated with maximum tolerated dose chemotherapy (MTDC), primarily using lomustine-based protocols and CHOP protocols, while 11 dogs received only prednisolone. The overall response rate for MTDC was 74.1%, but the median survival time was only 28 days (range, 3–421 days), with 6-month and 1-year survival rates of 9.4% and 3.1%, respectively. On multivariable analysis, monocytosis and peripheral blood involvement were significantly associated with shorter progression-free interval (PFI) and overall survival time (OST), while intermediate lymphocyte size correlated with better survival outcomes (≥100 days).
Important Findings
This study provides critical insights into LGLL in dogs, highlighting its aggressive nature and the limited efficacy of current treatments. The identification of key prognostic factors, such as blood involvement and cytologic features, is important for guiding future therapeutic approaches. No significant difference was observed in the likelihood of treatment response, PFI, or OST between dogs treated with or without lomustine-based induction chemotherapy, although this should be further investigated in a larger population. The fact that only 1 of 11 cases where histopathology was performed had visible azurophilic cytoplasmic granules highlights the importance of cytology in diagnosing and recognizing LGLL.
Study Limitations
The retrospective nature of this study, along with variability in diagnostic methods and non-standardized treatment protocols, limits the consistency and generalizability of the findings. Future research should focus on prospective studies and exploring more effective treatment strategies while validating the identified prognostic markers.
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyright © 2026 World Veterinary Oncology Consortium